TW202328180A - 包含pd-1及tgf-brii結合域之多特異性結合部分 - Google Patents
包含pd-1及tgf-brii結合域之多特異性結合部分 Download PDFInfo
- Publication number
- TW202328180A TW202328180A TW111144080A TW111144080A TW202328180A TW 202328180 A TW202328180 A TW 202328180A TW 111144080 A TW111144080 A TW 111144080A TW 111144080 A TW111144080 A TW 111144080A TW 202328180 A TW202328180 A TW 202328180A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- heavy chain
- tgf
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2029844 | 2021-11-19 | ||
| NL2029844 | 2021-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202328180A true TW202328180A (zh) | 2023-07-16 |
Family
ID=80625531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111144080A TW202328180A (zh) | 2021-11-19 | 2022-11-18 | 包含pd-1及tgf-brii結合域之多特異性結合部分 |
Country Status (18)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121152809A (zh) * | 2023-04-14 | 2025-12-16 | 因赛特公司 | 抗TGFβR2/PD-1双特异性抗体治疗癌症的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CN110198738A (zh) * | 2017-01-07 | 2019-09-03 | 默克专利有限公司 | 用于靶向的TGF-β抑制的给药方案和剂型 |
| TWI917306B (zh) * | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
| TWI887193B (zh) * | 2017-07-06 | 2025-06-21 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
-
2022
- 2022-11-18 MX MX2024006018A patent/MX2024006018A/es unknown
- 2022-11-18 CA CA3231649A patent/CA3231649A1/en active Pending
- 2022-11-18 PE PE2024001077A patent/PE20241477A1/es unknown
- 2022-11-18 WO PCT/EP2022/082377 patent/WO2023089083A1/en not_active Ceased
- 2022-11-18 AR ARP220103179A patent/AR127714A1/es unknown
- 2022-11-18 IL IL312214A patent/IL312214A/en unknown
- 2022-11-18 UY UY0001040028A patent/UY40028A/es unknown
- 2022-11-18 AU AU2022389596A patent/AU2022389596A1/en active Pending
- 2022-11-18 JP JP2024524389A patent/JP2024542879A/ja active Pending
- 2022-11-18 KR KR1020247019354A patent/KR20240101664A9/ko active Pending
- 2022-11-18 CR CR20240201A patent/CR20240201A/es unknown
- 2022-11-18 US US18/056,907 patent/US20230159645A1/en active Pending
- 2022-11-18 CN CN202411831660.4A patent/CN119613560A/zh active Pending
- 2022-11-18 CN CN202280076849.XA patent/CN118265725A/zh active Pending
- 2022-11-18 EP EP22818694.6A patent/EP4433505A1/en active Pending
- 2022-11-18 TW TW111144080A patent/TW202328180A/zh unknown
-
2024
- 2024-05-10 CL CL2024001410A patent/CL2024001410A1/es unknown
- 2024-05-17 CO CONC2024/0006325A patent/CO2024006325A2/es unknown
- 2024-05-21 EC ECSENADI202439278A patent/ECSP24039278A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022389596A1 (en) | 2024-05-30 |
| ECSP24039278A (es) | 2024-07-31 |
| PE20241477A1 (es) | 2024-07-17 |
| CL2024001410A1 (es) | 2024-08-30 |
| MX2024006018A (es) | 2024-07-29 |
| CN119613560A (zh) | 2025-03-14 |
| AR127714A1 (es) | 2024-02-21 |
| JP2024542879A (ja) | 2024-11-18 |
| US20230159645A1 (en) | 2023-05-25 |
| CA3231649A1 (en) | 2023-05-25 |
| IL312214A (en) | 2024-06-01 |
| KR20240101664A9 (ko) | 2025-12-10 |
| CN118265725A (zh) | 2024-06-28 |
| EP4433505A1 (en) | 2024-09-25 |
| KR20240101664A (ko) | 2024-07-02 |
| CR20240201A (es) | 2024-07-15 |
| WO2023089083A1 (en) | 2023-05-25 |
| CO2024006325A2 (es) | 2024-06-27 |
| UY40028A (es) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021184749A (ja) | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 | |
| US20210315933A1 (en) | Compositions and methods for tcr reprogramming using target specific fusion proteins | |
| JP2020202867A (ja) | キメラ受容体及びその使用方法 | |
| JP7022067B2 (ja) | Foxp3由来のペプチドに特異的なt細胞受容体様抗体 | |
| JP2022501428A (ja) | 抗lilrb2抗体およびその使用の方法 | |
| JP2024149487A (ja) | ホスファターゼ動員による受容体の阻害 | |
| TW201741337A (zh) | CD40L-Fc融合多肽及其使用方法 | |
| CN107835820A (zh) | 识别癌症特异性IL13Rα2的CAR T细胞 | |
| JP2006528626A (ja) | Nk細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
| TW202216745A (zh) | 包含經修飾il-2多肽之多肽及其用途 | |
| CN115989033B (zh) | 用于使用cd70特异性融合蛋白进行tcr重编程的组合物和方法 | |
| JP2022500484A (ja) | 抗ヒトvsig4抗体およびその使用 | |
| JP2023519644A (ja) | Ssea-4結合メンバー | |
| CN118715242A (zh) | 包含b7-h3结合多肽的组合物和方法 | |
| KR20230008144A (ko) | Cd19를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| US20210355220A1 (en) | Antibodies specific to ctla-4 and uses thereof | |
| US20230159645A1 (en) | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains | |
| TW202506711A (zh) | 切換受體 | |
| HK40129273A (en) | Switch receptors | |
| TW202019475A (zh) | Cd137結合分子 |